ARDELYX, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ARDELYX, INC. (ARDX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $54.07 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-11-07
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $14.81M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $16.29M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $22.97M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$59.23M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$131.08M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$3.45M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.86M.
- ARDELYX, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$278.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | $14.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $31.10M derived: sum of 2 quarters · filed 2017-11-07 | $54.07M 10-Q · filed 2017-11-07 | -$5.16M derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-06-30 | $16.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $39.26M 10-Q · filed 2017-08-09 | -$19.97M derived: sum of 3 quarters · filed 2017-08-09 | -$91.32M derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-03-31 | $22.97M 10-Q · filed 2017-05-05 | -$36.26M derived: sum of 2 quarters · filed 2017-05-05 | -$107.61M derived: sum of 3 quarters · filed 2017-11-07 | -$107.91M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-12-31 | -$59.23M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$130.58M derived: sum of 2 quarters · filed 2017-11-07 | -$130.88M derived: sum of 3 quarters · filed 2017-11-07 | -$131.08M 10-K · filed 2017-02-17 |
| 2016-09-30 | -$71.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$71.65M derived: sum of 2 quarters · filed 2017-11-07 | -$71.85M 10-Q · filed 2017-11-07 | -$72.30M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | -$295.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$495.00K 10-Q · filed 2017-08-09 | -$949.00K derived: sum of 3 quarters · filed 2017-08-09 | -$1.63M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | -$200.00K 10-Q · filed 2017-05-05 | -$654.00K derived: sum of 2 quarters · filed 2017-05-05 | -$1.33M derived: sum of 3 quarters · filed 2017-05-05 | -$2.60M derived: sum of 4 quarters · filed 2017-05-05 |
| 2015-12-31 | -$454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$1.13M derived: sum of 2 quarters · filed 2017-02-17 | -$2.40M derived: sum of 3 quarters · filed 2017-02-17 | -$3.45M 10-K · filed 2017-02-17 |
| 2015-09-30 | -$680.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$1.95M derived: sum of 2 quarters · filed 2016-11-07 | -$3.00M 10-Q · filed 2016-11-07 | -$4.03M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$2.32M 10-Q · filed 2016-08-08 | -$3.35M derived: sum of 3 quarters · filed 2017-02-17 | -$3.44M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$1.05M 10-Q · filed 2016-05-09 | -$2.09M derived: sum of 2 quarters · filed 2017-02-17 | -$2.17M derived: sum of 3 quarters · filed 2017-02-17 | -$2.82M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$1.12M derived: sum of 2 quarters · filed 2017-02-17 | -$1.76M derived: sum of 3 quarters · filed 2017-02-17 | -$1.86M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$730.00K derived: sum of 2 quarters · filed 2015-11-12 | -$824.00K 10-Q · filed 2015-11-12 | -$824.00K derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-06-30 | -$642.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$736.00K 10-Q · filed 2015-08-12 | -$736.00K derived: sum of 3 quarters · filed 2016-03-04 | -$757.00K derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-03-31 | -$94.00K 10-Q · filed 2015-05-12 | -$94.00K derived: sum of 2 quarters · filed 2016-03-04 | -$115.00K derived: sum of 3 quarters · filed 2016-03-04 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | -$21.00K derived: sum of 2 quarters · filed 2016-03-04 | -$278.00K 10-K · filed 2016-03-04 | |
| 2013-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$278.00K 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | -$257.00K 10-Q · filed 2014-08-08 | |||
| 2012-12-31 | -$128.00K 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |